Published in Jpn J Pharmacol on April 01, 1999
Benign prostatic hyperplasia: from bench to clinic. Korean J Urol (2012) 0.96
Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. Ther Clin Risk Manag (2011) 0.96
Comparing efficacy of α1D-receptor antagonist naftopidil and α1A/D-receptor antagonist tamsulosin in management of distal ureteral stones. World J Urol (2011) 0.96
In vivo studies on the effects of alpha1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.93
Management of benign prostatic hyperplasia with silodosin. Open Access J Urol (2009) 0.87
Selective α1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity. World J Urol (2009) 0.86
The role of naftopidil in the management of benign prostatic hyperplasia. Ther Adv Urol (2013) 0.85
Clinical feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms: a prospective study. Adv Urol (2011) 0.83
Naftopidil and tolterodine in the medical expulsive therapy for intramural ureteral stones: a prospective randomized study. Urol Res (2012) 0.83
Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine. Nat Clin Pract Urol (2009) 0.82
5-HT1A receptor pharmacophores to screen for off-target activity of α1-adrenoceptor antagonists. J Comput Aided Mol Des (2013) 0.82
Involvement of magnitude of ambient temperature change in nonspecific effect in perceived placebo effect on lower urinary tract symptoms: study on switching of naftopidil in patients with benign prostatic hyperplasia. Res Rep Urol (2013) 0.81
Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urol Ann (2014) 0.80
α(1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume. World J Urol (2010) 0.80
Ketanserin and Naftopidil Enhance the Potentiating Effect of Alpha-Methyl-Serotonin on the Neurally-Induced Contraction of Human Isolated Urinary Bladder Muscle Strips. Int Neurourol J (2017) 0.80
Functional alpha-1B adrenergic receptors on human epicardial coronary artery endothelial cells. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.79
Randomized controlled trial to compare the safety and efficacy of naftopidil and tamsulosin as medical expulsive therapy in combination with prednisolone for distal ureteral stones. Korean J Urol (2013) 0.79
Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil? Urol Ann (2016) 0.78
Search for new alpha1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia. Indian J Urol (2007) 0.78
Alpha 1-adrenoceptor blocker may improve not only voiding but also storage lower urinary tract symptoms caused by (125) I brachytherapy for prostate cancer. ISRN Urol (2014) 0.78
Hippocampal noradrenergic neurotransmission in concurrent EEG desynchronization and inhibition of penile erection induced by cocaine in the rat. Br J Pharmacol (2000) 0.76
Efficacy of silodosin in the treatment of distal ureteral stones 4 to 10 mm in diameter. Int J Clin Exp Med (2015) 0.76
Effects of Combination Treatment of Alpha 1-Adrenergic Receptor Antagonists on Voiding Dysfunction: Study on Target Organs in Overactive Bladder Rats. Int Neurourol J (2016) 0.75
Effects of Spinal and Peripheral Injection of α1A or α1D Adrenoceptor Antagonists on Bladder Activity in Rat Models with or without Bladder Outlet Obstruction. Int Neurourol J (2011) 0.75
Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan. Patient Prefer Adherence (2016) 0.75
Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study. Yonsei Med J (2017) 0.75
The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study. Urol Ann (2017) 0.75
Naftopidil versus flopropione as medical expulsive therapy for distal ureteral stones: results of a randomized, multicenter, double-blind, controlled trial. World J Urol (2015) 0.75
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Functional annotation of a full-length mouse cDNA collection. Nature (2001) 23.61
Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc (1987) 12.04
Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology (1990) 6.34
Delineating developmental and metabolic pathways in vivo by expression profiling using the RIKEN set of 18,816 full-length enriched mouse cDNA arrays. Proc Natl Acad Sci U S A (2001) 6.07
High-efficiency full-length cDNA cloning by biotinylated CAP trapper. Genomics (1996) 4.41
Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 3.93
Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes. Genome Res (2000) 3.78
Choice in the repeated-gambles experiment. J Exp Anal Behav (1988) 3.57
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet (1999) 2.81
Nonsense mutation of glucokinase gene in late-onset non-insulin-dependent diabetes mellitus. Lancet (1992) 2.71
A prolactin-releasing peptide in the brain. Nature (1998) 2.43
Type I phosphatidylinositol-4-phosphate 5-kinases. Cloning of the third isoform and deletion/substitution analysis of members of this novel lipid kinase family. J Biol Chem (1998) 2.42
Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med (1992) 2.30
Two pigment proteins in spinach chloroplasts. Biochim Biophys Acta (1966) 2.27
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer (2008) 2.19
Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation (1987) 2.15
Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol Cell Biol (1994) 2.13
Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia (1993) 2.11
Risk of bile duct carcinogenesis after excision of extrahepatic bile ducts in pancreaticobiliary maljunction. Surgery (1999) 2.09
Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol (2000) 2.04
Clinical studies of cefazolin in the surgical field. Antimicrob Agents Chemother (Bethesda) (1970) 2.03
Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. Transplantation (1989) 2.03
The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol Cell Biol (1995) 1.97
Reconstitution of catecholamine-stimulated guanosinetriphosphatase activity. Biochemistry (1983) 1.87
Reactions of glyoxal with nucleic acids. Nucleotides and their component bases. Biochim Biophys Acta (1968) 1.83
Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1beta. Circulation (1997) 1.83
The impact of stratospheric ozone recovery on the Southern Hemisphere westerly jet. Science (2008) 1.82
Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke (1998) 1.79
Balanced-size and long-size cloning of full-length, cap-trapped cDNAs into vectors of the novel lambda-FLC family allows enhanced gene discovery rate and functional analysis. Genomics (2001) 1.76
Computer-based methods for the mouse full-length cDNA encyclopedia: real-time sequence clustering for construction of a nonredundant cDNA library. Genome Res (2001) 1.75
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther (1998) 1.74
Energy charge, phosphorylation potential and proton motive force in chloroplasts. Biochim Biophys Acta (1980) 1.74
RGS8 accelerates G-protein-mediated modulation of K+ currents. Nature (1997) 1.73
Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet (1999) 1.61
Cloning of cDNAs encoding two isoforms of 68-kDa type I phosphatidylinositol-4-phosphate 5-kinase. J Biol Chem (1996) 1.59
Studies with antipeptide antibody suggest the presence of at least two types of glucose transporter in rat brain and adipocyte. J Biol Chem (1988) 1.59
Picture imperfect: hidden problems among Asian Pacific islander elderly. Gerontologist (1995) 1.57
Frequent p53 accumulation in the chronically sun-exposed epidermis and clonal expansion of p53 mutant cells in the epidermis adjacent to basal cell carcinoma. J Invest Dermatol (1995) 1.55
Comparative evaluation of 5'-end-sequence quality of clones in CAP trapper and other full-length-cDNA libraries. Gene (2001) 1.53
Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins (1977) 1.53
Massive actin polymerization induced by phosphatidylinositol-4-phosphate 5-kinase in vivo. J Biol Chem (1997) 1.51
In vivo evaluation of NM441, a new thiazeto-quinoline derivative. Antimicrob Agents Chemother (1991) 1.49
Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res (1999) 1.48
A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene. J Biol Chem (1996) 1.47
Screening of patients with maternally transmitted diabetes for mitochondrial gene mutations in the tRNA[Leu(UUR)] region. Diabet Med (1997) 1.46
Effects of staphylococcal enterotoxin B on intestinal transport in the rat. Am J Physiol (1971) 1.45
Decreased circulation time in the upper limb reduces the lag time of the finger pulse oximeter response. Can J Anaesth (1992) 1.43
Identification of three human type-II classic cadherins and frequent heterophilic interactions between different subclasses of type-II classic cadherins. Biochem J (2000) 1.41
Clinical importance of extraordinary integration patterns of human T-cell lymphotropic virus type I proviral DNA in adult T-cell leukemia/lymphoma. Blood (1994) 1.41
Overexpression of catalytic subunit p110alpha of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes. J Biol Chem (1996) 1.39
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer (2006) 1.39
A quick and simple method for the identification of meat species and meat products by PCR assay. Meat Sci (1999) 1.39
Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol (1996) 1.38
Prolongation of canine renal allograft survival by treatment with FK-506. Transplant Proc (1987) 1.38
Carcinoma of the gallbladder associated with anomalous junction of the pancreaticobiliary duct in adults. J Am Coll Surg (1999) 1.38
Copurification of small heat shock protein with alpha B crystallin from human skeletal muscle. J Biol Chem (1992) 1.37
p85alpha gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-Kinase), p50alpha, p55alpha, and p85alpha, with different PI 3-kinase activity elevating responses to insulin. J Biol Chem (1997) 1.37
Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature (1994) 1.37
Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats. Diabetes (1998) 1.37
KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol (1995) 1.34
Maximizing present value: A model to explain why moderate response rates obtain on variable-interval schedules. J Exp Anal Behav (1988) 1.33
Automated filtration-based high-throughput plasmid preparation system. Genome Res (1999) 1.33
Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity. Mol Cell Biol (2001) 1.32
14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J Biol Chem (1997) 1.32
T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes (1999) 1.32
Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. J Neurosci (2000) 1.28
C-terminal truncated glucose transporter is locked into an inward-facing form without transport activity. Nature (1990) 1.27
Human blood platelet 3': 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase. Biochim Biophys Acta (1976) 1.26
Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology (2000) 1.26
In vitro antibacterial activity of a new quinolone, NM394. Antimicrob Agents Chemother (1991) 1.25
Purification and characterization of a 20-kDa protein that is highly homologous to alpha B crystallin. J Biol Chem (1994) 1.25
Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci (2001) 1.25
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer (2010) 1.25
Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor. Biochem Biophys Res Commun (1993) 1.25
New sources and instrumentation for neutrons in biology. Chem Phys (2008) 1.24
Successful combined operation for mitral stenosis and atrial fibrillation. Ann Thorac Surg (1993) 1.24
Reconstitution of catecholamine-stimulated binding of guanosine 5'-O-(3-thiotriphosphate) to the stimulatory GTP-binding protein of adenylate cyclase. Biochemistry (1984) 1.24
MCM3AP, a novel acetyltransferase that acetylates replication protein MCM3. EMBO Rep (2001) 1.23
Intraductal papillary mucinous tumors of the pancreas. Am J Surg (1999) 1.23
Gelation of Limulus amoebocyte lysate by an antitumor (1 leads to 3)-beta-D-glucan. Biochem Biophys Res Commun (1981) 1.23
Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes (2000) 1.22
Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer (2007) 1.22
Metabolism of vitamin D in animals. V. Isolation of vitamin D sulfate from mammalian milk. J Vitaminol (Kyoto) (1967) 1.21
Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli. Biochem Biophys Res Commun (1985) 1.21
Toll-like receptors, NOD1, and NOD2 in oral epithelial cells. J Dent Res (2006) 1.19
The Fyn tyrosine kinase binds Irs-1 and forms a distinct signaling complex during insulin stimulation. J Biol Chem (1996) 1.18
Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther (2002) 1.18
Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci U S A (1995) 1.17
Defect in negative selection in lpr donor-derived T cells differentiating in non-lpr host thymus. J Exp Med (1991) 1.16
Successful endoscopic injection sclerotherapy with N-butyl-2-cyanoacrylate following the recurrence of bleeding soon after endoscopic ligation for ruptured duodenal varices. Am J Gastroenterol (1997) 1.15
Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br J Pharmacol (1989) 1.15